UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB41: TB and HIV

    11/05/2012 Alison Neathey
    Off
    Meetings

    Programme:

    09:30 – 09:50 Registration, refreshments and expenses
    09:50 – 10:00 Welcome, introductions, UKCAB updates
    10:00 – 11:15 TB and HIV: Screening and treatment– Dr Santino Capocci, Royal Free Hospital
    11:15 – 11.30 Break
    11:30 – 12.15 TB-HIV: Strengthening Community Response. – Gitau Mburu, Int. HIV/AIDS Alliance
    12:15 – 12.45 Company pre-meeting on TMC207 – Polly Clayden, HIV i-Base
    12:45 – 14:00 Lunch
    14:15 – 15:30 Company meeting: Janssen
    15.30 – 15.35 Break
    15:35 – 16:00 UKCAB London drug survey feedback – Mark Platt
    16.00 Close

    Background reading

    What is TB? – Extracted from the i-Base treatment training for advocates
    http://i-base.info/ttfa/5-opportunistic-infections-ois-and-coinfections/5-7-tb

    BHIVA guidelines for the treatment of TB/HIV coinfection 2011:
    http://www.bhiva.org/TB-HIV2011.aspx

    How TB is treated
    http://www.tbonline.info/posts/2011/9/2/how-tb-treated/

    Medicines for people with TB – contains 1st line, multi-drug resistant TB and extremely drug resistant TB medicines.  There is also a section on pipeline drugs.
    http://www.tbonline.info/medicines/

    Global TB drug pipeline:
    http://www.newtbdrugs.org/pipeline.php

    Faster conversion rates with TMC-207 versus placebo plus OBT for the treatment of MDR-TB – study on a new drug with the potential to improve both drug-sensitive and multi-drug resistant TB.
    http://i-base.info/htb-south/1330/

    2011 pipeline report: 2nd edition (September 2011) – covers the most recent and exciting developments in HIV, hepatitis and TB research. [PDF download, 1MB]
    http://i-base.info/home/2011-pipeline-report-2nd-edition-september-2011/

    TB in our Lives – A detailed guide by Treatment Action Campaign in South Africa, with emphasis on coinfection with HIV.  Activists wrote the guide about how TB attacks the body, how it is treated and the things they can do to help fight TB in their communities.

    They explain things in a way that makes sense and that is not too technical so that readers can go on and explain about TB to others. The guide has information sheets for people living with TB, support groups and clinics. [PDF download]
    http://www.tac.org.za/community/node/2115

    Other useful links:
    http://www.tbalert.org
    http://www.thetruthabouttb.org/
    http://www.tballiance.org/
    http://www.stoptbuk.org/

    Financial support

    The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

    The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

    We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

    For a list of companies that support the UK-CAB please see the “about us” page.

    Meetings
    Meetings